Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 402 3.07%
12 May - close price
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1) Biosimilars (58% in FY25 vs 50% in FY23): [1] [2] Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. [3] It is one of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in the top 15 companies worldwide for biomanufacturing capacity and has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development. [4]

The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets. [5]

Website BSE NSE
  • Market Cap ₹ 65,225 Cr.
  • Current Price ₹ 402
  • High / Low ₹ 425 / 328
  • Stock P/E 273
  • Book Value ₹ 167
  • Dividend Yield 0.12 %
  • ROCE 1.92 %
  • ROE 1.24 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 92.7%
  • Company's working capital requirements have reduced from 103 days to 35.9 days

Cons

  • Promoter holding has decreased over last quarter: -9.54%
  • The company has delivered a poor sales growth of 2.96% over past five years.
  • Company has a low return on equity of 0.94% over last 3 years.
  • Company has high debtors of 156 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
507 513 519 563 533 511 525 563 644 537 583 621 605
551 441 452 492 480 466 488 532 582 516 530 548 525
Operating Profit -44 72 67 71 52 45 38 31 62 21 53 73 79
OPM % -9% 14% 13% 13% 10% 9% 7% 6% 10% 4% 9% 12% 13%
1,918 56 64 48 39 42 74 672 63 61 134 -122 31
Interest 48 48 55 56 40 55 60 65 57 56 67 2 17
Depreciation 29 30 31 31 30 30 30 34 33 33 34 34 36
Profit before tax 1,796 50 46 33 22 1 21 604 35 -8 86 -84 57
Tax % -1% 6% 25% 27% 36% 18% 85% 3% 39% 9% 17% -10% 11%
1,811 47 35 24 14 1 3 584 21 -8 71 -76 51
EPS in Rs 15.08 0.39 0.29 0.20 0.12 0.01 0.03 4.86 0.18 -0.06 0.53 -0.57 0.31
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,242 2,302 2,588 2,419 1,786 1,988 2,028 1,738 1,993 2,127 2,243 2,346
1,812 1,880 1,996 2,101 1,575 1,702 1,716 1,677 1,969 1,864 2,066 2,120
Operating Profit 430 422 592 318 210 286 312 61 24 264 177 226
OPM % 19% 18% 23% 13% 12% 14% 15% 4% 1% 12% 8% 10%
127 279 99 125 422 366 150 187 3,134 206 848 105
Interest 1 2 4 1 3 1 0 0 70 199 237 142
Depreciation 128 140 151 136 92 98 104 108 117 121 128 137
Profit before tax 428 559 536 306 537 553 359 140 2,971 150 661 51
Tax % 16% 34% 3% 22% 8% 20% 22% 38% 4% 21% 8% 27%
361 369 519 238 493 441 280 86 2,848 119 609 37
EPS in Rs 3.01 3.07 4.33 1.99 4.11 3.67 2.34 0.72 23.72 0.99 5.07 0.23
Dividend Payout % 28% 27% 12% 25% 12% 0% 0% 70% 6% 50% 10% 218%
Compounded Sales Growth
10 Years: 0%
5 Years: 3%
3 Years: 6%
TTM: 5%
Compounded Profit Growth
10 Years: -2%
5 Years: -3%
3 Years: 171%
TTM: 432%
Stock Price CAGR
10 Years: 14%
5 Years: 1%
3 Years: 18%
1 Year: 23%
Return on Equity
10 Years: 2%
5 Years: 1%
3 Years: 1%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 100 100 100 300 300 600 600 600 600 600 600 810
Reserves 2,484 5,897 6,441 6,439 6,815 6,937 7,307 7,493 10,316 10,312 10,924 26,269
82 370 134 133 71 4 2 77 1,301 2,043 2,876 1,153
667 732 794 855 1,054 770 665 699 813 813 1,221 1,038
Total Liabilities 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621 29,271
914 894 938 903 1,101 793 798 870 961 958 1,114 1,399
CWIP 58 172 241 318 254 152 179 285 344 560 701 523
Investments 165 3,853 3,888 4,199 4,093 4,953 5,413 5,280 9,271 9,318 11,383 24,978
2,196 2,179 2,402 2,307 2,792 2,413 2,184 2,434 2,454 2,932 2,424 2,371
Total Assets 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768 15,621 29,271

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
125 208 186 355 110 387 478 48 219 -123 624 -180
145 -313 104 -553 315 -189 -628 -302 -1,173 -295 -992 -6,582
-158 73 -238 -55 -208 -129 28 112 1,039 344 495 6,602
Net Cash Flow 112 -32 52 -252 217 69 -122 -142 86 -74 127 -160
Free Cash Flow 67 -11 -42 186 -148 195 420 -197 -45 -429 302 -469
CFO/OP 48% 98% 52% 139% 117% 167% 173% 124% 1,103% -36% 376% -70%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 90 80 113 112 184 105 106 147 121 180 135 156
Inventory Days 148 187 190 195 371 236 197 245 208 260 296 299
Days Payable 109 146 159 202 298 230 170 172 169 175 288 201
Cash Conversion Cycle 129 121 144 105 257 111 133 220 159 265 143 254
Working Capital Days 76 42 108 87 214 154 122 181 151 244 30 36
ROCE % 17% 10% 8% 4% 5% 5% 5% 2% 2% 3% 2% 2%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend (Ex-Syngene)
% of Revenue

Log in to view insights

Please log in to see hidden values.

Login
Patient Reach
Million
Regulatory Approvals Received (Annual)
Number
Global Presence (Countries)
Countries
Market Share - Fulphila (bPegfilgrastim) US
%
API Manufacturing Capacity
Metric Tons
Market Share - Ogivri (bTrastuzumab) US
%
Oral Solid Dosage (OSD) Capacity
Million Units
Total Product Launches (Annual)
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 54.45% 54.45% 54.45% 44.91%
9.52% 7.97% 6.55% 5.63% 5.90% 5.93% 5.66% 5.67% 6.04% 6.61% 7.39% 7.52%
12.59% 14.08% 14.51% 13.69% 14.29% 14.44% 15.36% 15.73% 22.83% 22.06% 21.67% 24.01%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.05%
16.77% 16.92% 17.96% 19.74% 18.90% 18.74% 18.11% 17.77% 16.51% 16.70% 16.34% 23.40%
0.49% 0.39% 0.33% 0.32% 0.28% 0.25% 0.22% 0.21% 0.18% 0.14% 0.12% 0.09%
No. of Shareholders 4,12,4414,15,0464,34,3394,70,2614,43,5134,39,5034,27,7054,24,2974,28,1314,13,1913,94,2793,86,593

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls